AL58922

AL58922 is a small-molecule dual inhibitor targeting phosphoinositide 3-kinase alpha (PI3Kα) and the mechanistic target of rapamycin (mTOR). Developed by Hangzhou Aidecheng Pharmaceutical Technology (Advenchen), the compound is designed to inhibit the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in various human cancers. By simultaneously targeting both PI3Kα and mTOR, AL58922 aims to provide more comprehensive pathway blockade and potentially mitigate resistance compared to selective inhibitors. As of the latest pipeline updates, the drug has completed preclinical development and is in the IND-enabling phase, preparing for clinical trial applications.